Tandem Diabetes Care, Inc. announced that its t:connect(TM) Diabetes Management Application, the web-based data management companion to the t:slim(R) Insulin Pump, has been cleared for use by the U.S. Food and Drug Administration. The t:connect Application is a Mac and PC-compatible data management software application that provides t:slim Pump users and their healthcare providers a fast, easy, and visual way to display data from the pump and supported blood glucose meters. This software empowers users to quickly and easily identify meaningful information and patterns, which allows them to fine-tune therapy and lifestyle choices for improved diabetes management. The t:connect Application makes pump and meter data simple to understand with color-coded graphs and interactive reports. Data uploads from the t:slim Pump to the t:connect Application through a micro-USB connection without interrupting insulin delivery.

Tandem Diabetes Care, Inc. announced the appointment of Lonnie Smith as Chairman of its Board of Directors. Mr. Smith is Chairman of the Board and former chief executive officer of Intuitive Surgical. He succeeds Dick Allen, who will continue as a member of the Board. Lonnie Smith's career in the medical device industry spans more than four decades. Mr. Smith is Chairman of the Board and an executive officer of Intuitive Surgical, where he previously served as chief executive officer from May 1997 to January 1, 2010. Prior to joining Intuitive Surgical, Mr. Smith was senior executive vice president for Hillenbrand Industries, and he has also held positions with The Boston Consulting Group and IBM Corporation.

Tandem Diabetes Care, Inc. announced a partnership with Juvenile Diabetes Research Foundation International Inc. (JDRF) to develop a first-of-its-kind, dual-chamber infusion pump for the management of diabetes. The partnership agreement is designed to accelerate the development of a next-generation, fully automated artificial pancreas system using therapies in conjunction with insulin. JDRF will support Tandem in performance-based milestone funding over the next two years to complete the development, testing, and manufacturing of a novel infusion pump that can simultaneously deliver two injectable hormonal drug therapies.